This inhibitor showed promising results in clinically aggressive histotypes of poorly differentiated and high-grade mucinous CRC which also carried KRAS- and BRAF-activating mutations, representing an unmet medical need, and uncovered cadherin-17 as a valuable negative predictor of CRC sensitivity to this inhibitor [68]. The gene discussed is CDH17; the disease is colorectal carcinoma.